A Comparative Assessment of Quality of Life in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.
Martino M et al. Biol Blood Marrow Transplant. 2017 Oct 12. pii: S1083-8791(17)30764-4. doi: 10.1016/j.bbmt.2017.09.021. [Epub ahead of print].
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
Jakubowiak AJ et al. Expert Rev Hematol. 2017 Oct 13. doi: 10.1080/17474086.2017.1391088. [Epub ahead of print].
Plasma cell myeloma mimicking classical Hodgkin lymphoma in the bone marrow.
Karner KH et al. Int J Hematol. 2017 Oct 13. doi: 10.1007/s12185-017-2343-9. [Epub ahead of print].
Treat or palliate: Outcomes of hyperelderly myeloma patients.
Panitsas F et al. Haematologica. 2017 Oct 12. pii: haematol.2017.173617. doi: 10.3324/haematol.2017.173617. [Epub ahead of print].
An Incidental Finding of Maternal Multiple Myeloma by Non Invasive Prenatal Testing.
Imbert-Bouteille M et al. Prenat Diagn. 2017 Oct 12. doi: 10.1002/pd.5168. [Epub ahead of print].
Minimal residual disease analysis in myeloma – when, why and where.
Yanamandra U et al. Leuk Lymphoma. 2017 Oct 11:1-13. doi: 10.1080/10428194.2017.1386304. [Epub ahead of print].
Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J et al. Curr Res Transl Med. 2017 Oct 5. pii: S2452-3186(17)30030-2. doi: 10.1016/j.retram.2017.08.003. [Epub ahead of print].
Impact of “New Drugs” on the Long-Term Follow-Up of Upfront Tandem Auto-Allo Transplant in Multiple Myeloma.
Giaccone L et al. Biol Blood Marrow Transplant. 2017 Oct 4. pii: S1083-8791(17)30750-4. doi: 10.1016/j.bbmt.2017.09.017. [Epub ahead of print].
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
Yan X et al. Clin Pharmacokinet. 2017 Oct 5. doi: 10.1007/s40262-017-0598-1. [Epub ahead of print].
“Hof” in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
Thakral B et al. Blood. 2017 Sep 28;130(13):1600. doi: 10.1182/blood-2017-07-796466.
Epigenetics in multiple myeloma: From mechanisms to therapy.
Alzrigat M et al. Semin Cancer Biol. 2017 Sep 27. pii: S1044-579X(17)30104-9. doi: 10.1016/j.semcancer.2017.09.007. [Epub ahead of print].
Disease and Symptom Care: A Focus on Specific Needs of Patients With Multiple Myeloma
.
Faiman B. Clin J Oncol Nurs. 2017 Oct 1;21(5):3-6. doi: 10.1188/17.CJON.S5.3-6.
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey.
Landgren O et al. Blood Cancer J. 2017 Oct 20;7(10):e618. doi: 10.1038/bcj.2017.97.
Utilization of agents to prevent skeletal-related events among patients with multiple myeloma: analysis of real-world data.
Qian Y et al. Support Care Cancer. 2017 Oct 23. doi: 10.1007/s00520-017-3892-4. [Epub ahead of print].
Minimal residual disease in multiple myeloma: Benefits of flow cytometry.
Galtseva IV et al. Int J Lab Hematol. 2017 Oct 23. doi: 10.1111/ijlh.12757. [Epub ahead of print].
Donor T-cell responses and disease progression patterns of multiple myeloma.
Hefting M et al. Bone Marrow Transplant. 2017 Oct 2. doi: 10.1038/bmt.2017.201. [Epub ahead of print].